Review



nilotinib  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress nilotinib
    (a) Dose–response viability curves of K562 and KCL22 cells treated with dasatinib (left panels), <t>nilotinib</t> (middle panels), or ponatinib (right panels), alone or in combination with fixed doses of BI-3406 (1 nM, 10 nM, or 100 nM). BI-3406 monotherapy had minimal effect on viability but markedly potentiated the cytotoxic activity of all three TKIs in both cell lines, resulting in a pronounced reduction in ICDD values (see table in panel c). (b) Synergy analysis of BI-3406 in combination with dasatinib, nilotinib, or ponatinib using the ZIP model. 3D surface plots show areas of synergy (red) across concentration matrices. ZIP synergy scores >10 denote strong combinatorial interaction. Synergistic effects were observed in all conditions, with particularly high scores for Nilotinib combinations. Data presented as mean ± SEM from three independent replicates. ICDD values were calculated after 48 h treatment.
    Nilotinib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 45 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nilotinib/product/MedChemExpress
    Average 93 stars, based on 45 article reviews
    nilotinib - by Bioz Stars, 2026-02
    93/100 stars

    Images

    1) Product Images from "Targeting SOS1 synergistically enhances efficacy of BCR/ABL tyrosine kinase inhibitors and overcomes resistance in chronic myeloid leukemia"

    Article Title: Targeting SOS1 synergistically enhances efficacy of BCR/ABL tyrosine kinase inhibitors and overcomes resistance in chronic myeloid leukemia

    Journal: bioRxiv

    doi: 10.1101/2025.09.29.679122

    (a) Dose–response viability curves of K562 and KCL22 cells treated with dasatinib (left panels), nilotinib (middle panels), or ponatinib (right panels), alone or in combination with fixed doses of BI-3406 (1 nM, 10 nM, or 100 nM). BI-3406 monotherapy had minimal effect on viability but markedly potentiated the cytotoxic activity of all three TKIs in both cell lines, resulting in a pronounced reduction in ICDD values (see table in panel c). (b) Synergy analysis of BI-3406 in combination with dasatinib, nilotinib, or ponatinib using the ZIP model. 3D surface plots show areas of synergy (red) across concentration matrices. ZIP synergy scores >10 denote strong combinatorial interaction. Synergistic effects were observed in all conditions, with particularly high scores for Nilotinib combinations. Data presented as mean ± SEM from three independent replicates. ICDD values were calculated after 48 h treatment.
    Figure Legend Snippet: (a) Dose–response viability curves of K562 and KCL22 cells treated with dasatinib (left panels), nilotinib (middle panels), or ponatinib (right panels), alone or in combination with fixed doses of BI-3406 (1 nM, 10 nM, or 100 nM). BI-3406 monotherapy had minimal effect on viability but markedly potentiated the cytotoxic activity of all three TKIs in both cell lines, resulting in a pronounced reduction in ICDD values (see table in panel c). (b) Synergy analysis of BI-3406 in combination with dasatinib, nilotinib, or ponatinib using the ZIP model. 3D surface plots show areas of synergy (red) across concentration matrices. ZIP synergy scores >10 denote strong combinatorial interaction. Synergistic effects were observed in all conditions, with particularly high scores for Nilotinib combinations. Data presented as mean ± SEM from three independent replicates. ICDD values were calculated after 48 h treatment.

    Techniques Used: Activity Assay, Concentration Assay



    Similar Products

    Image Search Results